CD19 and diffuse large B-cell lymphoma: Furthermore, tafasitamab-cxix (MorphoSys US), which is a humanized Fc-modified cytolytic CD19 targeting mAb, has been approved by FDA in combination with lenalidomide for the treatment of RR DLBCL patient.